JP2017132781A5 - - Google Patents

Download PDF

Info

Publication number
JP2017132781A5
JP2017132781A5 JP2017038701A JP2017038701A JP2017132781A5 JP 2017132781 A5 JP2017132781 A5 JP 2017132781A5 JP 2017038701 A JP2017038701 A JP 2017038701A JP 2017038701 A JP2017038701 A JP 2017038701A JP 2017132781 A5 JP2017132781 A5 JP 2017132781A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
formula
free form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017038701A
Other languages
English (en)
Japanese (ja)
Other versions
JP6340103B2 (ja
JP2017132781A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017132781A publication Critical patent/JP2017132781A/ja
Publication of JP2017132781A5 publication Critical patent/JP2017132781A5/ja
Application granted granted Critical
Publication of JP6340103B2 publication Critical patent/JP6340103B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017038701A 2011-09-06 2017-03-01 ベンゾチアゾロン化合物 Expired - Fee Related JP6340103B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNPCT/CN2011/079379 2011-09-06
CN2011079379 2011-09-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014529113A Division JP6130835B2 (ja) 2011-09-06 2012-09-05 ベンゾチアゾロン化合物

Publications (3)

Publication Number Publication Date
JP2017132781A JP2017132781A (ja) 2017-08-03
JP2017132781A5 true JP2017132781A5 (enExample) 2017-10-19
JP6340103B2 JP6340103B2 (ja) 2018-06-06

Family

ID=47010668

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014529113A Expired - Fee Related JP6130835B2 (ja) 2011-09-06 2012-09-05 ベンゾチアゾロン化合物
JP2017038701A Expired - Fee Related JP6340103B2 (ja) 2011-09-06 2017-03-01 ベンゾチアゾロン化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2014529113A Expired - Fee Related JP6130835B2 (ja) 2011-09-06 2012-09-05 ベンゾチアゾロン化合物

Country Status (39)

Country Link
US (6) US8933108B2 (enExample)
EP (1) EP2753609B1 (enExample)
JP (2) JP6130835B2 (enExample)
KR (2) KR101800140B1 (enExample)
CN (2) CN103781771B (enExample)
AP (1) AP3830A (enExample)
AR (1) AR087787A1 (enExample)
AU (1) AU2013200422C1 (enExample)
BR (1) BR112014004732A2 (enExample)
CA (1) CA2845766A1 (enExample)
CL (1) CL2014000493A1 (enExample)
CO (1) CO6900147A2 (enExample)
CR (1) CR20140114A (enExample)
CU (1) CU24303B1 (enExample)
CY (1) CY1118585T1 (enExample)
DK (1) DK2753609T3 (enExample)
EA (1) EA022909B1 (enExample)
ES (1) ES2615052T3 (enExample)
GT (1) GT201400042A (enExample)
HR (1) HRP20170075T1 (enExample)
HU (1) HUE030530T2 (enExample)
IL (1) IL231235A (enExample)
JO (1) JO3192B1 (enExample)
LT (1) LT2753609T (enExample)
MX (1) MX345405B (enExample)
MY (1) MY163301A (enExample)
PE (1) PE20141993A1 (enExample)
PH (1) PH12014500399A1 (enExample)
PL (1) PL2753609T3 (enExample)
PT (1) PT2753609T (enExample)
RS (1) RS55468B1 (enExample)
SG (1) SG2014013114A (enExample)
SI (1) SI2753609T1 (enExample)
TN (1) TN2014000060A1 (enExample)
TW (1) TWI555738B (enExample)
UA (1) UA114295C2 (enExample)
UY (1) UY34312A (enExample)
WO (1) WO2013035047A1 (enExample)
ZA (2) ZA201401112B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3192B1 (ar) 2011-09-06 2018-03-08 Novartis Ag مركب بنزوثيازولون
UA117092C2 (uk) 2011-09-06 2018-06-25 Байєр Інтеллектуал Проперті Гмбх Амінозаміщені імідазопіридазини
ES2642003T3 (es) * 2012-08-30 2017-11-14 Novartis Ag Sales de un compuesto de benzotiazolona como agonistas del adreno-receptor beta-2
ES2646916T3 (es) 2012-11-19 2017-12-18 Bayer Pharma Aktiengesellschaft Aminoimidazopiridazinas como inhibidores de MKNK1 cinasa
MA38354B1 (fr) * 2013-02-28 2016-09-30 Novartis Ag Préparation contenant un composé de benzothiazolone
US10967119B1 (en) 2019-04-01 2021-04-06 Azizi Bilal Wearable medication injecting device

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0662324A1 (en) * 1987-09-15 1995-07-12 The Rowett Research Institute Use of beta-adrenergic agonists for treating loss of function of striated muscles
US20070082918A1 (en) * 1993-11-02 2007-04-12 Naftchi N E Neurologically active compounds and compounds with multiple activities
GB9405019D0 (en) 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel compounds
ZA967892B (en) 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
WO1999009018A1 (en) 1997-08-14 1999-02-25 Kirin Beer Kabushiki Kaisha BENZOTHIAZOLONE DERIVATIVES HAVING SELECTIVE β2 RECEPTOR AGONIST ACTIVITY
CA2349616A1 (en) 1998-12-04 2000-06-15 Neurosearch A/S New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US6872723B2 (en) * 2002-01-28 2005-03-29 Wyeth Stabilized difloxacin injectable solution
US6743797B2 (en) * 2002-02-22 2004-06-01 Chantest, Inc. Methods for treating cardiac arrhythmia
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
PE20050130A1 (es) 2002-08-09 2005-03-29 Novartis Ag Compuestos organicos
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
EP1631260A2 (en) 2003-02-28 2006-03-08 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2004085058A1 (en) * 2003-03-26 2004-10-07 Pharmacia & Upjohn Company Llc Process to produce enantiomerically enriched alcohols and amines
AU2004226824B2 (en) * 2003-04-04 2008-05-01 Novartis Ag Quinoline-2-one-derivatives for the treatment of airways diseases
JP2007503472A (ja) * 2003-06-10 2007-02-22 カリプシス・インコーポレーテッド 病気治療用のヒストン脱アセチル化酵素阻害剤としてのカルボニル化合物
WO2004110418A2 (en) 2003-06-10 2004-12-23 Kalypsys, Inc. Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease
EP1646370A1 (en) 2003-07-11 2006-04-19 Glaxo Group Limited Pharmaceutical formulations
JP2009513531A (ja) 2003-07-11 2009-04-02 グラクソ グループ リミテッド 糖エステルを含む吸入可能医薬製剤
US7345060B2 (en) 2003-11-21 2008-03-18 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
GB0328490D0 (en) 2003-12-09 2004-01-14 Glaxo Group Ltd Medicinal compounds
JP2005187357A (ja) 2003-12-25 2005-07-14 Nippon Suisan Kaisha Ltd 選択的なβ2受容体アゴニスト活性を有するベンゾチアゾロン誘導体の製造方法
GB0402797D0 (en) * 2004-02-09 2004-03-10 Novartis Ag Organic compounds
JP2007537187A (ja) 2004-05-13 2007-12-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器疾患の治療においてβアゴニストとして使用するためのヒドロキシ置換ベンゾ縮合ヘテロ環化合物
EP1595873A1 (de) 2004-05-13 2005-11-16 Boehringer Ingelheim Pharma GmbH & Co.KG Substituierte Cycloalkylderivate zur Behandlung von Atemswegerkrankungen
JP2008507532A (ja) 2004-07-21 2008-03-13 セラヴァンス, インコーポレーテッド ジアリールエーテルβ2アドレナリン作用性レセプターアゴニスト
DE102004045648A1 (de) 2004-09-21 2006-03-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika zur Behandlung von Atemwegserkrankungen
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
DE102005007654A1 (de) 2005-02-19 2006-08-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
TW200738659A (en) 2005-08-29 2007-10-16 Astrazeneca Ab Novel compounds
TW200740781A (en) 2005-08-29 2007-11-01 Astrazeneca Ab Novel compounds
WO2007086078A2 (en) 2006-01-30 2007-08-02 Panacea Biotec Ltd. Novel pharmaceutical compositions and process of preparation thereof
CA2641880C (en) 2006-02-10 2014-09-09 Summit Corporation Plc Treatment of duchenne muscular dystrophy
TW200745084A (en) 2006-03-08 2007-12-16 Astrazeneca Ab Novel compounds
GB0613154D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
BRPI0716495A2 (pt) * 2006-08-10 2014-03-04 Us Gov Health & Human Serv (r,r)-fenoterol e análogos de (r,r)- ou (r,s)-fenoterol, uso dos mesmos na preparação de composição farmacêutica e composição farmacêutica compreendendo o referidos compostos.
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
TW200911237A (en) 2007-08-03 2009-03-16 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
GB0814728D0 (en) 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination
GB0823140D0 (en) 2008-12-18 2009-01-28 Astrazeneca Ab New combination
GB201009801D0 (en) 2010-06-11 2010-07-21 Astrazeneca Ab Compounds 950
GB201107985D0 (en) 2011-05-13 2011-06-29 Astrazeneca Ab Process
JO3192B1 (ar) 2011-09-06 2018-03-08 Novartis Ag مركب بنزوثيازولون
ES2642003T3 (es) * 2012-08-30 2017-11-14 Novartis Ag Sales de un compuesto de benzotiazolona como agonistas del adreno-receptor beta-2
MA38354B1 (fr) 2013-02-28 2016-09-30 Novartis Ag Préparation contenant un composé de benzothiazolone

Similar Documents

Publication Publication Date Title
JP2017132781A5 (enExample)
JP2017531038A5 (enExample)
JP2016121196A5 (enExample)
JP2006514626A5 (enExample)
JP2006509749A5 (enExample)
JP2010529147A5 (enExample)
CN112368281A (zh) 作为pde3/pde4双重抑制剂的三并环类化合物
JP2009501732A5 (enExample)
JP2020511461A5 (enExample)
JP2009531376A5 (enExample)
JP2017512789A5 (enExample)
JP2012522847A5 (enExample)
JP2009502743A5 (enExample)
JP2017520613A5 (enExample)
JP2018537535A5 (enExample)
JP2019519593A5 (enExample)
JP2020097577A5 (enExample)
CN115315423A (zh) 取代芳基类化合物
CN114829365A (zh) 作为erk抑制剂的噻唑并内酰胺类化合物及其应用
JP2014526554A5 (enExample)
CN111788205A (zh) 吡唑并嘧啶衍生物及其用途
CN114728967A (zh) 作为jak抑制剂的三并杂环类化合物及其应用
JP2017518982A5 (enExample)
JP2005500370A5 (enExample)
HRP20170075T1 (hr) Spoj benzotiazolona